Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.00 Average PT from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Hold” from the nine analysts that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $10.00.

ZNTL has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Guggenheim reduced their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $3.06 on Tuesday. The firm has a market cap of $218.07 million, a PE ratio of -1.23 and a beta of 1.84. The firm’s 50 day simple moving average is $3.34 and its 200-day simple moving average is $3.68. Zentalis Pharmaceuticals has a one year low of $2.66 and a one year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Equities research analysts predict that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Anfield Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $40,000. Erste Asset Management GmbH purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at $37,000. Paloma Partners Management Co acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals in the 3rd quarter worth $41,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth about $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.